|

Volrustomig Clinical Trials

14 actively recruiting trials across 9 locations

Also known as: MEDI5752, Other Name: MEDI5752

Los Angeles, California4 trials

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Research Site

Phase 2
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Research Site

Phase 2
Volrustomig Priming Regimens Exploratory Phase II Platform Study

Research Site

Phase 2

Birmingham, Alabama2 trials

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Research Site

Phase 2
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Research Site

Phase 3

Sacramento, California2 trials

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

UC Davis

Early 1
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

UC Davis

Early 1

Phoenix, Arizona1 trial

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Research Site

Phase 3

Scottsdale, Arizona1 trial

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Research Site

Phase 2

Little Rock, Arkansas1 trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site

Phase 2

Duarte, California1 trial

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Research Site

Phase 1

Santa Monica, California1 trial

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Research Site

Phase 2

Chicago, Illinois1 trial

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

The University of Chicago

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.